文献速递瓣膜外科

瓣周反流对经导管与外科主动脉瓣置换中期结局的影响

Impact of paravalvular regurgitation on the mid-term outcome after transcatheter and surgical aortic valve replacement.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

基于芬兰FinnValve全国登记研究,纳入2008-2017年6463例因主动脉瓣狭窄行TAVR(n=2130)或SAVR(n=4333)并使用生物瓣的患者,评估出院时瓣周反流(PVR)对4年死亡率的影响。TAVR后轻度及中重度PVR均为生存变差的独立预测因素;SAVR后PVR不常见,但亦呈生存下降趋势,多变量分析未达统计学显著。

要点

  • TAVR后轻度PVR发生率21.7%,中重度3.7%;SAVR后分别为5.2%和0.7%。
  • TAVR后轻度PVR(校正HR 1.64,95%CI 1.35-1.99)和中重度PVR(校正HR 1.61,95%CI 1.10-2.35)均与4年生存变差独立相关。
  • SAVR后PVR与4年生存下降相关但多变量分析未达统计学显著。

核心结论

  • TAVR后轻度和中重度PVR均为生存变差的独立预测因素。
  • SAVR后轻度和中重度PVR不常见,但亦倾向于降低生存。

研究设计与样本

  • 基于芬兰FinnValve全国登记研究的多中心队列分析。
  • 纳入2008-2017年6463例因主动脉瓣狭窄行TAVR(n=2130)或SAVR(n=4333)并使用生物瓣的连续患者。
  • 评估出院时PVR对4年死亡率的影响。

主要发现

  • TAVR后轻度PVR发生率21.7%,中重度3.7%;SAVR后分别为5.2%和0.7%。
  • TAVR后4年生存:无至微量PVR 69.0%,轻度PVR 54.2%(校正HR 1.64,95%CI 1.35-1.99),中重度PVR 48.9%(校正HR 1.61,95%CI 1.10-2.35)。
  • TAVR后免于PVR相关再干预:无至轻度PVR 100%,中重度PVR 95.2%。
  • SAVR后4年生存:无至微量PVR 83.7%,轻度PVR 78.9%(校正HR 1.29,95%CI 0.93-1.78),中重度PVR 67.8%(校正HR 1.36,95%CI 0.72-2.58),多变量分析未达统计学显著。
  • SAVR后免于PVR相关再干预:无至微量PVR 99.5%,轻度PVR 97.9%,中重度PVR 77.0%。

临床怎么用

  • TAVR术后应重视出院时PVR评估,轻度PVR亦与远期生存下降相关。
  • SAVR术后PVR发生率较低,但中重度PVR仍需关注再干预风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to evaluate the incidence and prognostic impact of paravalvular regurgitation (PVR) on the outcome after transcatheter (TAVR) and surgical aortic valve replacement (SAVR) for aortic stenosis. METHODS: The nationwide FinnValve registry included data on 6463 consecutive patients who underwent TAVR (n = 2130) or SAVR (n = 4333) with a bioprosthesis for the treatment of aortic stenosis during 2008-2017. The impact of PVR at discharge after TAVR and SAVR on 4-year mortality was herein investigated. RESULTS: The rate of mild PVR was 21.7% after TAVR and 5.2% after SAVR. The rate of moderate-to-severe PVR was 3.7% after TAVR and 0.7% after SAVR. After TAVR, 4-year survival was 69.0% in patients with none-to-trace PVR, 54.2% with mild PVR [adjusted hazard ratio (HR) 1.64, 95% confidence interval (CI) 1.35-1.99] and 48.9% with moderate-to-severe PVR (adjusted HR 1.61, 95% CI 1.10-2.35). Freedom from PVR-related reinterventions was 100% for none-to-mild PVR and 95.2% for moderate-to-severe PVR. After SAVR, mild PVR (4-year survival 78.9%; adjusted HR 1.29, 95% CI 0.93-1.78) and moderate-to-severe PVR (4-year survival 67.8%; adjusted HR 1.36, 95% CI 0.72-2.58) were associated with worse 4-year survival compared to none-to-trace PVR (4-year survival 83.7%), but the difference did not reach statistical significance in multivariable analysis. Freedom from PVR-related reinterventions was 99.5% for none-to-trace PVR patients, 97.9% for mild PVR patients and 77.0% for moderate-to-severe PVR patients. CONCLUSIONS: This multicentre study showed that both mild and moderate-to-severe PVR were independent predictors of worse survival after TAVR. Mild and moderate-to-severe PVR are not frequent after SAVR, but tend to decrease survival also in these patients. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT03385915.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Laakso T, Laine M, Moriyama N, et al. Impact of paravalvular regurgitation on the mid-term outcome after transcatheter and surgical aortic valve replacement. Eur J Cardiothorac Surg. 2020. PMID: 33057657. doi:10.1093/ejcts/ezaa254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。